Author:
Garattini Livio,Casadei Gianluigi
Abstract
Italy is one of the few countries that have matured substantial experience of risk-sharing agreements so far. The first performance-based arrangement was agreed in July 2006, and as of October 2010, eighteen contracts have been in force.The complex management of discount schemes is entirely based on Web registries run by AIFA, the Italian drug agency. The system validates each prescription and automatically requests the hospital pharmacy by e-mail to release the drug. If a patient meets nonresponder criteria, the hospital pharmacist should apply for pay-back to the manufacturer.There are still some important question marks to address. First of all, nonresponders have to be documented by health authorities, otherwise any undocumented nonresponder will be paid as a success. Another question concerns pre-set timing. Although the scientific rationale of the nonresponder criteria for each drug has not been made public, time frames appear too short to allow a reliable assessment. Another question is whether regions, which are financially accountable in Italy for pharmaceutical expenditure, are really able to claw back refunds from manufacturers. Unfortunately here again there are no official figures, and regions do not seem yet able to quantify the amount of pay-back matured in the 4 previous years. The delayed and incomplete availability of pay-back procedures may be one explanation.
Publisher
Cambridge University Press (CUP)
Reference8 articles.
1. 1. AIFA – Agenzia Italiana del Farmaco. Allineamento Procedure di Gestione Rimborsi Cost/Risk Share e Payment by Result. Rome, November 13, 2009. http://antineoplastici.agenziafarmaco.it/Comunicato_Procedure_Gestione_Rimborsi.pdf (accessed October 8, 2010).
2. Multiple sclerosis risk sharing scheme: a costly failure
3. Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional health care providers
4. 2. AIFA – Agenzia Italiana del Farmaco. Determinazione 24 Luglio 2006. Regime di rimborsabilità e prezzo di vendita della specialita’ medicinale Tarceva (erlotinib). http://antineoplastici.agenziafarmaco.it/tarceva.pdf (accessed October 8, 2010).
5. 3. AIFA – Agenzia Italiana del Farmaco. Farmaci sottoposti a monitoraggio. http://monitoraggio-farmaci.agenziafarmaco.it/ (accessed November 15, 2010.
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献